What Pricing Pressure? Recordati Continues Push Into Turkey With Latest Acquisition
This article was originally published in PharmAsia News
Executive Summary
Although many pharma companies are reducing investments in Turkey after a series of controversial government price cuts, Italian drug maker Recordati S.p.A is doing just the opposite, buying Istanbul-based Dr. F. Frick Ilac for $130 million earlier this month, its second acquisition in Turkey in three years. Recordati, in fact, sees significant growth opportunities in Turkey and Eastern European, and says more deals could be on the way
You may also be interested in...
Italy’s Recordati Starts $50 Million Greenfield Investment In Turkey
Italian pharmaceutical company Recordati invests $50 million in Turkey to establish a production facility in Tekirdag province to produce cardiovascular drugs.
Earnings Briefs: Actavis, Celgene, InterMune, Lilly, Forest
Companies are reporting out their half-year earnings and giving investors updates on the progress of their pipelines, as well as ongoing launch plans. Actavis and Warner Chilcott are in line as their merger approaches; Lilly’s Lechleiter gives an update on BD plans; AbbVie talks about its HCV combo; and Shire recommits to ADHD promotion.
Amgen Shrugs Off Turkish Price Cuts, Snatches Up Mustafa Nevzat For Broader Reach Into Emerging Markets
Despite harsh price cuts in Turkey that have taken a toll on multinationals, Amgen dives head first into the market.